Join KBI Biopharma at World ADC London in March 2024. Be sure to stop by and chat with our team of experts. We look forward to seeing you in London!
KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 500+ client partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond.
Antibody-drug conjugates are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. Notable achievements include the ground-shaking triumph of ENHERTU, eye-popping investments like Pfizer's monumental $43 billion acquisition of Seagen, and the FDA’s greenlight for ELAHERE. These milestones have transformed the ADC landscape, driving increased interest and investment in the field, which now has a preclinical and clinical arena dynamically evolving.
As such, the 14th World ADC London returns next March. This will be the first opportunity in the new year to explore these monumental wins, reflect on ongoing challenges, and collaborate on innovative strategies to supercharge all stages of ADC development.